Therapeutic antibodies and infectious diseases, Tours, France, November 20−22, 2012

Abstract

The Therapeutic Antibodies and Infectious Diseases international congress was held in Tours, France on November 20−22, 2012. The first session was devoted to the development of antibodies directed against bacterial toxins or viruses that could be used in a potential bioterrorist threat situation. The second session dealt with the effector functions of anti-microbial antibodies, while the third was oriented toward anti-viral antibodies, with a special emphasis on antibodies directed against the human immunodeficiency and hepatitis C viruses. After a lecture by a speaker from the US Food and Drug Administration on antibody cocktails, the second day ended with a special session dedicated to discussions regarding the involvement of French biotechnology industries in the field. On the last day, the congress concluded with talks about current antibody treatments for infectious diseases, with a particular focus on their adverse events. Participants enjoyed this very stimulating and convivial meeting, which gathered scientists from various countries who had different scientific research interests.

Generation of Neutralizing Monoclonal Antibodies against a Conformational Epitope of Human Adenovirus Type 7 (HAdv-7) Incorporated in Capsid Encoded in a HAdv-3-Based Vector

“…Therapeutic MAbs are promising as biological drugs that provide protection from infectious diseases [25] , [26] . Some pathogens are produced in in vitro culture with poor yields or cannot be propagated in cell lines.…”

MAbImprove

“…Consistent with its project based on the clinical use of therapeutic antibodies, these meetings address questions related to clinically relevant issues. Past meetings were devoted to “Therapeutic antibodies and anaphylaxis” (Tours, June 2011), 6 “Therapeutic antibodies and infectious diseases” (Tours, November 2012) 7 and “Therapeutic antibodies and cancer: tools and models to understand and improve their efficacy” (Montpellier, November 2013).…”

Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives

“…The attrition of existing therapeutic options and emergence of new viruses has complicated the management of RTIs, increasing pressure on healthcare systems and motivated the development of new therapeutic strategies for RTIs. Among these, antibodies (Abs), and antibody-based molecules, are now considered as a viable option against emerging viral pathogens and antibiotic-resistant bacteria [5][6][7][8][9].…”